Is Spyre Therapeutics Inc. (SYRE) overvalued? · $7.60B cap
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
This page asks whether Spyre Therapeutics Inc. (SYRE) looks expensive on cached numbers — not a short thesis.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
SYRE currently screens at market cap $7.60B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SYRE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SYRE stock page for the full model, not this heading.
Not investment advice.